Study of GV1001 injection for moderate to severe Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests an investigational drug called GV1001, given as a small injection under the skin, to see if it can help slow down memory and thinking problems in people with moderate to severe Alzheimer's disease. The trial lasts for a period of time and involves regular check-ups and cognitive tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 55 and 85 years old.
- You must have a confirmed diagnosis of probable Alzheimer's disease with moderate to severe symptoms (score of 19 or lower on a standard memory test).
- You must be currently taking donepezil (Aricept) alone or donepezil combined with memantine (Namenda) at a stable dose for at least 3 months.
- You must be able to walk (with or without a cane or walker) to visit the clinic for tests.
- You must have a caregiver who can attend all study visits and help with study tasks.
- You must not have other conditions that cause dementia, such as vascular dementia, Parkinson's disease, or certain psychiatric disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
Hear when a new Moderate to Severe Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.